Expert Opinion on Investigational Drugs

Top Research Topics at Expert Opinion on Investigational Drugs?

Pharmacology, Internal medicine, Clinical trial, Immunology and Disease are among the topics commonly tackled in Expert Opinion on Investigational Drugs. The journal holds forums on Pharmacology that merges themes from other disciplines such as Receptor and Cancer. Expert Opinion on Investigational Drugs investigates Cancer research which frequently intersects with Cancer research.

Gastroenterology, Endocrinology, Oncology and Cardiology are some topics wherein Internal medicine research discussed in it have an impact. Diabetes mellitus is a focus of the presented Endocrinology works and it dives deep in Diabetes mellitus. The in-depth study on Oncology also explores topics in the intersecting field of Breast cancer.

The Cardiology study tackling the subject of Heart failure is the focus of it. The Clinical trial study featured in Expert Opinion on Investigational Drugs draws connections with the study of Intensive care medicine. Immune system, Inflammation and Immunotherapy are all areas of Immunology tackled in it.

• Pharmacology (32.42%)
• Internal medicine (27.70%)
• Clinical trial (18.31%)

What are the most cited papers published in the journal?

• American Association for Cancer Research (501 citations)
• Glioblastoma multiforme: a review of where we have been and where we are going (390 citations)
• Targeting STAT3 in cancer: how successful are we? (328 citations)

Research areas of the most cited articles at Expert Opinion on Investigational Drugs:

The journal publications mainly tackle studies in Pharmacology, Internal medicine, Cancer research, Immunology and Clinical trial. The most cited papers focus on Pharmacology but sometimes tackle the closely related topic of Cancer which is concerned with Angiogenesis. The journal articles with studies in Internal medicine featured incorporate elements of Endocrinology and Oncology.

What topics the last edition of the journal is best known for?

• Internal medicine
• Cancer
• Disease

The previous edition focused in particular on these issues:

The journal mostly deals with topics like Internal medicine, Clinical trial, Oncology, Disease and Immunotherapy. While work presented in Expert Opinion on Investigational Drugs provided substantial information on Clinical trial, it also covered topics in Chronic hepatitis and Drug. In the journal, Monoclonal antibody and Virology are investigated in conjunction with one another to address concerns in Drug research.

Expert Opinion on Investigational Drugs mainly concentrates on Oncology but also investigates its connection with concepts in disciplines such as

• Cancer and related Immune system,
• Precision medicine that connect with fields like Computational biology.. The study of Disease encompasses disciplines such as Neuroscience, as well as fields such as Dementia, all of which overlap with one another. Immunotherapy research presented in it encompasses a variety of subjects, including Liver cancer, Hepatocellular carcinoma, Cancer research and Malignancy.

The most cited articles from the last journal are:

• Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. (35 citations)
• Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies (10 citations)
• Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. (9 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Expert Opinion on Investigational Drugs (based on the number of publications) are:

• Sheila A Doggrell (59 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• Sabina A Antoniu (30 papers) absent at the last edition,
• John F. Barrett (25 papers) absent at the last edition,
• Simone Ferrero (19 papers) published 1 paper at the last edition, 2 less than at the previous edition,
• Jerry R. Colca (16 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Expert Opinion on Investigational Drugs (based on the number of publications) are:

• University of Texas MD Anderson Cancer Center (68 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• National Institutes of Health (51 papers) published 3 papers at the last edition, 1 more than at the previous edition,
• Harvard University (48 papers) published 4 papers at the last edition, 1 less than at the previous edition,
• National and Kapodistrian University of Athens (45 papers) published 3 papers at the last edition, 2 more than at the previous edition,
• Mayo Clinic (45 papers) published 8 papers at the last edition, 3 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 12.73% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 25.00% were posted by at least one author from the top 10 institutions publishing in the journal. Another 10.42% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 22.92% of all publications and 41.67% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Research Opportunities in the Field of Pharmacology and Internal Medicine

Expert Opinion on Investigational Drugs has been a cornerstone in providing research papers related to Pharmacology and Internal Medicine. However, it is also important to note that the field is continually evolving, offering numerous opportunities for newer research topics.

Development in disease prevention and therapeutic alternatives are among the key areas where more research is needed. For example, studying the efficiency of early detection methods in mitigating the spread of infectious diseases would create preventative strategies and could directly improve patient outcomes. The approach to designing patient-centered care models is another field that needs exploration, as it has a direct bearing on how health care services are delivered in the future.

For those who are interested in undertaking a career in pharmacological and internal medicine research, it is important to be cognizant of the landscape of your chosen field. Accessing resources like the kentucky nursing license requirements nursing license cost, could provide relevant information on career requirements and opportunities.

In addition, understanding licensing rules, examining research availability and potential collaboration with a host institution can help shape future research. These types of assessments not only provide practical guidance to aspiring researchers, but also contribute to the overall growth and quality of research presented in Expert Opinion on Investigational Drugs.